Ibrutinib: ikhambi lokulwa ne-lymphoma ne-leukemia

-Delile

• Intengo
• Ungathatha kanjani
• Imiphumela emibi engaba khona
• Ubani okungafanele athathe

Ibrutinib isidakamizwa esingasetshenziswa ukwelapha i-mantle cell lymphoma kanye ne-leukemia engapheli, njengoba ikwazi ukuvimba isenzo sephrotheni elibhekele ukusiza amangqamuzana omdlavuza ukuba akhule futhi ande.

Lo muthi ukhiqizwa ngamalabhorethri okwenziwa ngawo iJanssen ngaphansi kwegama elithi Imbruvica futhi angathengwa emakhemisi ajwayelekile angamaphilisi ayi-140 mg.

Intengo

Intengo ye-Ibrutinib iyahluka phakathi kwama-reais angama-39,000 kanye nama-50,000, futhi ingathengwa emakhemisi lapho kwethulwa incwadi kadokotela.

Ungathatha kanjani

Ukusetshenziswa kwe-Ibrutinib kufanele kuqondiswe njalo yi-oncologist, noma kunjalo, izinkomba ezijwayelekile zomuthi zikhomba ukungeniswa kwamaphilisi ama-4 kanye ngosuku, okungcono ngasikhathi sinye.

Ama-capsules kufanele agwinywe ephelele, ngaphandle kokuphuka noma ukuhlafuna, kanye nengilazi yamanzi.

Imiphumela emibi engaba khona

Eminye yemiphumela emibi kakhulu ye-Ibrutinib ifaka ukukhathala okuvamile, ukutheleleka kwamakhala, izindawo ezibomvu noma nsomi esikhunjeni, imfiva, izimpawu zomkhuhlane, ukuqola nobuhlungu bomzimba, amasinusi noma umphimbo.

Ubani okungafanele athathe

Lesi sidakamizwa siphikisiwe ezinganeni nasebusheni, kanye nakwiziguli ezinokungezwani komzimba nanoma yiziphi izingxenye zefomula. Ngaphezu kwalokho, akufanele zisetshenziswe ngokuhlanganyela namakhambi okwelapha ukwelashwa kokucindezeleka okuqukethe iSt John's Wort.

Ibrutinib akufanele futhi isetshenziswe ngabesifazane abakhulelwe noma abancelisayo, ngaphandle kosizo lukadokotela wokubelethisa.